EP0362371A4 - Il-2 receptor-specific chimeric antibodies - Google Patents

Il-2 receptor-specific chimeric antibodies

Info

Publication number
EP0362371A4
EP0362371A4 EP19890905832 EP89905832A EP0362371A4 EP 0362371 A4 EP0362371 A4 EP 0362371A4 EP 19890905832 EP19890905832 EP 19890905832 EP 89905832 A EP89905832 A EP 89905832A EP 0362371 A4 EP0362371 A4 EP 0362371A4
Authority
EP
European Patent Office
Prior art keywords
receptor
chimeric antibodies
specific chimeric
specific
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19890905832
Other versions
EP0362371A1 (en
Inventor
Cary L. Queen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PDL Biopharma Inc
Original Assignee
Protein Design Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Design Labs Inc filed Critical Protein Design Labs Inc
Publication of EP0362371A1 publication Critical patent/EP0362371A1/en
Publication of EP0362371A4 publication Critical patent/EP0362371A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
EP19890905832 1988-04-15 1989-04-13 Il-2 receptor-specific chimeric antibodies Withdrawn EP0362371A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18186288A 1988-04-15 1988-04-15
US181862 1988-04-15

Publications (2)

Publication Number Publication Date
EP0362371A1 EP0362371A1 (en) 1990-04-11
EP0362371A4 true EP0362371A4 (en) 1990-10-24

Family

ID=22666118

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19890905832 Withdrawn EP0362371A4 (en) 1988-04-15 1989-04-13 Il-2 receptor-specific chimeric antibodies

Country Status (6)

Country Link
EP (1) EP0362371A4 (en)
JP (1) JPH02503867A (en)
KR (1) KR900700134A (en)
AU (1) AU631545B2 (en)
FI (1) FI895955A0 (en)
WO (1) WO1989009622A1 (en)

Families Citing this family (160)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
PT92900A (en) * 1989-01-24 1990-07-31 EXPRESSION VECTOR SYSTEM FOR THE PRODUCTION OF QUIMERIC MONOCLONAL ANTIBODIES
FR2649488A1 (en) * 1989-07-07 1991-01-11 Inst Nat Sante Rech Med FRAGMENTS OF MONOCLONAL ANTIBODIES SPECIFIC TO THE PRESENCE OF ACTIVE LEUKOCYTES - THEIR PROCESS FOR OBTAINING AND THEIR APPLICATION IN THE CASE OF A GRAFT REJECT
DE10399023I2 (en) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-binding proteins
US5196320A (en) * 1989-09-20 1993-03-23 Abbott Biotech, Inc. Method of producing engineered binding proteins
FR2652746A1 (en) * 1989-10-06 1991-04-12 Merieux Inst APPLICATION OF ACTIVE AGENTS FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF LYMPHOMA OR THE LIKE.
FR2652747B1 (en) * 1989-10-06 1995-03-31 Merieux Inst APPLICATION OF ACTIVE AGENTS FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF AUTOIMMUNE DISEASES.
GR1001050B (en) * 1990-01-09 1993-04-28 Protein Design Labs Inc Particular human immunoglobulin receiver of il-2 new type
HUT60768A (en) 1990-03-16 1992-10-28 Sandoz Ag Process for producing cd25 fixing molecules
DE4018442A1 (en) * 1990-06-08 1991-12-12 Boehringer Mannheim Gmbh RECOMBINANT DNA AND METHOD FOR PRODUCING CHIMERIC ANTIBODIES
DE4028955A1 (en) * 1990-09-12 1992-03-19 Boehringer Mannheim Gmbh MONOCLONAL ANTIBODIES AGAINST THE INTERLEUKIN 2 RECEPTOR
GB9020282D0 (en) 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
US6277969B1 (en) * 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
LU91067I2 (en) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and immunochemical derivatives including immotoxins
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6146850A (en) 1991-11-04 2000-11-14 Xoma Corporation Proteins encoding gelonin sequences
US5837491A (en) * 1991-11-04 1998-11-17 Xoma Corporation Polynucleotides encoding gelonin sequences
US5621083A (en) * 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US5869619A (en) * 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
DE69233204T2 (en) * 1991-12-13 2004-07-15 Xoma Corp., Berkeley METHOD AND MATERIALS FOR THE PRODUCTION OF MODIFIED VARIABLE ANTIBODY DOMAINS AND THEIR THERAPEUTIC USE
DE19543039C1 (en) * 1995-11-08 1996-11-21 Medac Klinische Spezialpraep DNA mols. encoding CD30-specific immunoglobulin variable regions
CN1215340A (en) 1996-02-09 1999-04-28 安姆根有限公司 Composition comprising interleukin-1 inhibitor and controlled release polymer
US6013256A (en) * 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
AU736876B2 (en) 1996-12-06 2001-08-02 Amgen, Inc. Combination therapy using an IL-1 inhibitor for treating IL-1 mediated diseases
EP1724282B1 (en) 1997-05-21 2013-05-15 Merck Patent GmbH Method for the production of non-immunogenic proteins
ATE372349T1 (en) * 1998-07-27 2007-09-15 Novartis Pharma Gmbh USE OF BASILIXIMAB TO TREAT RHEUMATOID ARTHRITIS AND SKIN DISEASES
EE200100603A (en) 1999-05-14 2003-02-17 Imclone Systems Incorporated Treatment of human refractory tumors with epidermal growth factor receptor antagonists
WO2001002853A2 (en) 1999-07-05 2001-01-11 K.U. Leuven Research & Development DETECTION OF VON-WILLEBRANDFACTOR (vWF) ACTIVITY
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
US7071319B2 (en) 2000-05-16 2006-07-04 Thomas Jefferson University Recombinant antibodies, and compositions and methods for making and using the same
DE60136174D1 (en) 2000-05-16 2008-11-27 Univ Jefferson RABIESVIRUS-SPECIFIC NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES AND NUCLEIC ACIDS AND RELATED METHODS
MXPA03007316A (en) 2001-02-19 2003-12-04 Merck Patent Gmbh Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity.
WO2004002500A1 (en) * 2002-06-28 2004-01-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of treating autoimmune diseases with interferon-beta and il-2r antagonist
EP1575416B1 (en) 2002-07-19 2013-10-02 Beth Israel Deaconess Medical Center Methods of diagnosing pre-eclampsia
US7435419B2 (en) 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
CA2537263C (en) 2002-11-27 2017-05-30 Minerva Biotechnologies Corporation Techniques and compositions for the diagnosis and treatment of cancer (muc1)
EP2365001A3 (en) 2003-05-01 2012-03-28 Imclone LLC Fully human antibodies directed against the human insulin-like growth factor-1 receptor
CA2544365A1 (en) 2003-11-01 2005-05-12 Biovation, Ltd. Modified anti-cd52 antibody
EP2070947B1 (en) 2003-12-05 2014-06-11 multimmune GmbH Therapeutic and diagnostic anti-Hsp70 antibodies
WO2005090407A1 (en) 2004-03-19 2005-09-29 Imclone Systems Incorporated Human anti-epidermal growth factor receptor antibody
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
WO2005116657A2 (en) 2004-05-24 2005-12-08 Universität Zu Köln Identification of ergothioneine transporter and therapeutic uses thereof
EP1602926A1 (en) 2004-06-04 2005-12-07 University of Geneva Novel means and methods for the treatment of hearing loss and phantom hearing
JP5265188B2 (en) 2004-08-26 2013-08-14 ザ ユニバーシティー オブ ウェスタン オンタリオ Method for identifying iron transport inhibitors in Staphylococcus aureus
MX2007003320A (en) 2004-09-24 2007-05-18 Amgen Inc Modified fc molecules.
KR20130119506A (en) 2004-09-24 2013-10-31 베스 이스라엘 데코니스 메디칼 센터 Methods of diagnosing and treating complications of pregnancy
ES2523457T3 (en) 2004-11-18 2014-11-26 Imclone Llc Antibodies against vascular endothelial growth factor receptor 1
EP1812064A4 (en) 2004-11-19 2009-07-08 Cornell Res Foundation Inc Use of vascular endothelial growth factor receptor 1+ cells in treating and monitoring cancer and in screening for chemotherapeutics
EP1875244B1 (en) 2005-03-30 2019-01-23 Minerva Biotechnologies Corporation Proliferation of muc1 expressing cells
ES2720288T3 (en) 2005-03-30 2019-07-19 Minerva Biotechnologies Corp Proliferation of cells expressing MUC1
EP1712557A1 (en) 2005-04-14 2006-10-18 RWTH Aachen New s-adenosyl-L-methionine analogues with extended activated groups for transfer by methyltransferases
DK2100618T3 (en) 2005-06-17 2014-03-03 Imclone Llc Anti-PDGFR alpha antibody for use in the treatment of metastatic bone cancer
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
DK1919954T3 (en) 2005-08-30 2017-01-30 Univ Miami Immune modulating tumor necrosis factor receptor (TNFR25) - agonists, antagonists and immunotoxins
WO2008010101A2 (en) 2006-07-18 2008-01-24 Sanofi-Aventis Antagonist antibody against epha2 for the treatment of cancer
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
EP1914242A1 (en) 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2094733A1 (en) 2006-11-03 2009-09-02 U3 Pharma GmbH Fgfr4 antibodies
PT2099826E (en) 2007-01-05 2014-01-09 Univ Zuerich Anti-beta-amyloid antibody and uses thereof
EP3159355A1 (en) 2007-03-13 2017-04-26 Universität Zürich Monoclonal human tumor-specific antibody
WO2008118324A2 (en) 2007-03-26 2008-10-02 Macrogenics, Inc. Composition and method of treating cancer with an anti-uroplakin ib antibody
KR100883430B1 (en) 2007-06-13 2009-02-12 한국생명공학연구원 Human Monoclonal Antibody Neutralizing Vesicular Endothelial Growth Factor Receptor and Use Thereof
GB2451928B (en) 2007-06-21 2011-03-16 Angelica Therapeutics Inc Modified Toxins
MX338474B (en) 2007-08-29 2016-04-18 Sanofi Aventis Humanized anti-cxcr5 antibodies, derivatives thereof and their uses.
EP2527369A3 (en) 2007-09-13 2012-12-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US8933202B2 (en) 2007-11-12 2015-01-13 U3 Pharma Gmbh AXL antibodies
BRPI0909633A2 (en) 2008-03-12 2015-09-22 Imclone Llc anti-tyrp1 antibodies
AR071891A1 (en) 2008-05-30 2010-07-21 Imclone Llc ANTI-FLT3 HUMAN ANTIBODIES (THIROSINE KINASE 3 RECEPTOR HUMAN FMS TYPE)
MX2011002478A (en) 2008-09-07 2011-04-05 Glyconex Inc Anti-extended type i glycosphingolipid antibody, derivatives thereof and use.
KR20110069144A (en) 2008-10-09 2011-06-22 미네르바 바이오테크놀로지 코포레이션 Method for inducing pluripotency in cells
SI2370466T1 (en) 2008-12-19 2015-11-30 Biogen International Neuroscience Gmbh Human anti-alpha-synuclein autoantibodies
AU2010280981B2 (en) 2009-08-05 2016-01-28 Nexigen Gmbh Human HCV-interacting proteins and methods of use
JP5925678B2 (en) 2009-08-18 2016-05-25 プレジデント アンド フェローズ オブ ハーバード カレッジ Methods and compositions for the treatment of proliferative and pathogenic diseases
WO2011024114A1 (en) 2009-08-25 2011-03-03 Ecole Polytechnique Federale De Lausanne (Epfl) Targeting extracellular matrix molecules for the treatment of cancer
EP2305285A1 (en) 2009-09-29 2011-04-06 Julius-Maximilians-Universität Würzburg Means and methods for treating ischemic conditions
AR078470A1 (en) 2009-10-02 2011-11-09 Sanofi Aventis ANTIBODIES THAT SPECIFICALLY JOIN THE EPHA2 RECEIVER
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
UA112288C2 (en) 2010-01-15 2016-08-25 Кірін-Емджен, Інк. Antibody forvulation and therapeutic regimens
JP5841072B2 (en) 2010-02-10 2016-01-06 イミュノジェン・インコーポレーテッド CD20 antibody and use thereof
WO2011103389A1 (en) 2010-02-19 2011-08-25 Cornell University Method to treat autoimmune demyelinating diseases and other autoimmune or inflammatory diseases
AR080698A1 (en) 2010-04-01 2012-05-02 Imclone Llc ANTIBODY OR FRAGMENT OF THE SAME THAT SPECIFICALLY LINKS THE VARIOUS OF HUMAN CSF -1R, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, ITS USE FOR THE MANUFACTURE OF A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF CANCER AND METHOD TO DETERMINE IF A BASED SUBJECT MATTER AND
WO2011145085A2 (en) 2010-05-21 2011-11-24 Procognia (Israel) Ltd Novel antibodies and methods of use for the treatment and diagnosis of cancer
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
WO2012025636A1 (en) 2010-08-27 2012-03-01 University Of Zurich Method for target and drug validation in inflammatory and/or cardiovascular diseases
WO2012028697A1 (en) 2010-09-01 2012-03-08 Eth Zürich, Institute Of Molecular Biology And Biophysics Affinity purification system based on donor strand complementation
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EA031698B1 (en) 2010-10-11 2019-02-28 Байоджен Интернэшнл Нейросайенз Гмбх Human anti-tau antibodies
EP2630160B1 (en) 2010-10-18 2016-11-09 MediaPharma S.r.l. Erbb3 binding antibody
US9283271B2 (en) 2010-12-17 2016-03-15 Neurimmune Holding Ag Human anti-SOD1 antibodies
WO2012104824A1 (en) 2011-02-04 2012-08-09 Ecole polytechnique fédérale de Lausanne (EPFL) Therapeutic antibodies targeting app-c99
WO2012113775A1 (en) 2011-02-21 2012-08-30 University Of Zurich Ankyrin g and modulators thereof for the treatment of neurodegenerative disorders
JP2014510730A (en) 2011-03-16 2014-05-01 サノフイ Use of dual V region antibody-like proteins
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
EP2530088A1 (en) 2011-05-30 2012-12-05 Klinikum rechts der Isar der Technischen Universität München Means and methods for diagnosing and treating multiple sclerosis
DK2723379T3 (en) 2011-06-23 2018-10-15 Biogen Int Neuroscience Gmbh ANTI-ALPHA SYNUCLEIN BINDING MOLECULES
DE202011103324U1 (en) 2011-07-12 2012-01-02 Nekonal S.A.R.L. Therapeutic anti-TIRC7 antibodies for use in immune and other diseases
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
MY183989A (en) 2011-09-19 2021-03-17 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
SG10201602654SA (en) 2011-10-03 2016-05-30 Moderna Therapeutics Inc Modified nucleosides,nucleotides,and nucleic acids,and uses thereof
EP2764118A1 (en) 2011-10-05 2014-08-13 University of Bremen Wnt4 and med12 for use in the diagnosis and treatment of tumor diseases
EP2602621A1 (en) 2011-12-08 2013-06-12 Julius-Maximilians-Universität Würzburg LASP-1, a novel urinary marker for transitional cell carcinoma detection
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
EP2794660A2 (en) 2011-12-23 2014-10-29 Phenoquest AG Antibodies for the treatment and diagnosis of affective and anxiety disorders
ES2964168T3 (en) 2011-12-28 2024-04-04 Immunoqure Ag Anti-interleukin 22 antibody (IL-22) and its uses
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
CN103382223B (en) 2012-04-01 2015-06-10 上海益杰生物技术有限公司 Multi-functional antibody polypeptide aiming at epidermal growth factor receptor (EGFR) cryptic epitope and T cell antigen
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013243950A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
EP4148135A1 (en) 2012-07-05 2023-03-15 The Trustees of the University of Pennsylvania U1 snrnp regulates gene expression and modulates oncogenicity
WO2014039513A2 (en) 2012-09-04 2014-03-13 The Trustees Of The University Of Pennsylvania Inhibition of diacylglycerol kinase to augment adoptive t cell transfer
EP2711016A1 (en) 2012-09-21 2014-03-26 Covagen AG Novel IL-17A binding molecules and medical uses thereof
DE102012020496A1 (en) 2012-10-18 2014-04-24 Charité - Universitätsmedizin Berlin Invitro diagnosis and/or early detection of neurofibromatosis type 1 and/or neurofibromatosis type 1-associated tumor from sample of a patient for treating the patient with the tumor, comprises detecting protein or its fragment in sample
PT2922554T (en) 2012-11-26 2022-06-28 Modernatx Inc Terminally modified rna
JP6284548B2 (en) 2012-12-21 2018-02-28 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Human anti-tau antibody
EP3517545A1 (en) 2012-12-31 2019-07-31 Neurimmune Holding AG Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2014150600A2 (en) 2013-03-15 2014-09-25 Angelica Therapeutics, Inc. Modified toxins
CN104140974B (en) 2013-05-08 2017-09-29 科济生物医药（上海）有限公司 Encode the nucleic acid of the Chimeric antigen receptor albumen of GPC 3 and express the T lymphocytes of the Chimeric antigen receptor albumen of GPC 3
ES2911663T3 (en) 2013-07-03 2022-05-20 Immunoqure Ag Human anti-IFN-alpha antibodies
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
US10323076B2 (en) 2013-10-03 2019-06-18 Modernatx, Inc. Polynucleotides encoding low density lipoprotein receptor
CN104774264B (en) 2014-01-15 2018-09-14 上海易乐生物技术有限公司 Anti-human proBDNF monoclonal antibodies and its effect in pain
ES2760002T3 (en) 2014-03-31 2020-05-12 Amgen K A Inc Methods of treating nail and scalp psoriasis
AU2015254596B2 (en) 2014-04-30 2020-10-22 Klinikum Rechts Der Isar Der Technischen Universitat Munchen Diagnosis of multiple sclerosis
TW201628647A (en) 2014-06-27 2016-08-16 賽諾菲公司 Anti-IL4-IL13 bispecific antibodies
CN112979828A (en) 2014-07-17 2021-06-18 恺兴生命科技(上海)有限公司 T lymphocyte targeting CLD18A2 and preparation method and application thereof
GB201415349D0 (en) 2014-08-29 2014-10-15 Univ Leuven Kath Cofactor analogues for methyltransferases
MY180054A (en) 2014-09-30 2020-11-20 Neurimmune Holding Ag Human-derived anti-dipeptide repeats (dprs) antibody
WO2016081796A1 (en) 2014-11-21 2016-05-26 Yale University Compositions and methods for modulating salm5 and hvem
MA41629A (en) 2015-03-04 2018-01-09 Center For Human Reproduction COMPOSITIONS AND METHODS OF USE OF ANTI-MÜLLERIAN HORMONE FOR THE TREATMENT OF INFERTILITY
RU2733496C2 (en) 2015-03-16 2020-10-02 Гельмгольц Центрум Мюнхен - Дойчес Форшунгсцентрум Фюр Гезундхайт Унд Умвельт (Гмбх) Trispecific binding molecules for treating viral hepatitis b infection and bound states
EP3271397B1 (en) 2015-03-18 2021-03-03 The Johns Hopkins University Inhibitory monoclonal antibody targeting potassium channel kcnk9
ITUB20155097A1 (en) 2015-11-05 2017-05-05 Biouniversa Srl Humanized anti-BAG3 antibodies
EP3202788A1 (en) 2016-02-05 2017-08-09 MediaPharma S.r.l. Endosialin-binding antibody
ITUA20162242A1 (en) 2016-04-01 2017-10-01 St Biochimico Italiano Giovanni Lorenzini Spa A NEW ANTI-ERBB2 ANTIBODY
JP2018035137A (en) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ Novel anti-fibroblast activated protein (FAP) binding agent and use thereof
US10316037B1 (en) 2016-11-04 2019-06-11 Yale University Compounds and methods for treating cancer
IT201600111877A1 (en) 2016-11-07 2018-05-07 Biouniversa Srl Anti-BAG3 antibodies in combination with inhibitors of immune check-point for therapeutic use
WO2018129029A1 (en) 2017-01-04 2018-07-12 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
WO2018129284A1 (en) 2017-01-05 2018-07-12 The Johns Hopkins University Development of new monoclonal antibodies recognizing human prostate-specific membrane antigen (psma)
TWI808963B (en) 2017-03-22 2023-07-21 法商賽諾菲公司 Treatment of lupus using humanized anti-cxcr5 antibodies
US10722589B2 (en) 2017-04-03 2020-07-28 Covagen Ag FGFR3 binding molecules
EP3784274A1 (en) 2018-04-27 2021-03-03 Fondazione Ebri Rita Levi-Montalcini Antibody directed against a tau-derived neurotoxic peptide and uses thereof
WO2019217450A1 (en) 2018-05-08 2019-11-14 Rhode Island Hospital Anti-chi3l1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatohepatitis and subsequent complications
WO2020014306A1 (en) 2018-07-10 2020-01-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
WO2020053808A1 (en) 2018-09-12 2020-03-19 Georg Dewald Method of diagnosing vasoregulatory disorders
WO2020099235A1 (en) 2018-11-12 2020-05-22 Mediapharma S.R.L. Bispecific antibodies directed against human 90k and either endosialin or her3
WO2020157122A1 (en) 2019-01-29 2020-08-06 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Treating the causative agent in adhesiogenesis
US11028176B2 (en) 2019-02-13 2021-06-08 The Brigham And Women's Hospital, Inc. Anti-peripheral lymph node addressin antibodies and uses thereof
MA56033A (en) 2019-05-24 2022-04-06 Sanofi Sa METHODS OF TREATMENT FOR GENERALIZED SCLERODERMA
WO2021140173A1 (en) 2020-01-10 2021-07-15 Biouniversa S.R.L. Methods and uses for treating fibrotic solid tumors with bags inhibitors
US11896619B2 (en) 2020-03-10 2024-02-13 Massachusetts Institute Of Technology Compositions and methods for immunotherapy of NPM1c-positive cancer
EP4305064A1 (en) 2021-03-12 2024-01-17 Fibrosys S.r.l. Monoclonal antibodies for the treatment of viral infections

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2188941A (en) * 1986-04-14 1987-10-14 Bayer Ag Monoclonal antibodies recognizing human interleukin-2-receptor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US664911A (en) * 1900-09-17 1901-01-01 William H Voss Mechanical movement.
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4664911A (en) * 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
EP0173494A3 (en) * 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
JPS61134325A (en) * 1984-12-04 1986-06-21 Teijin Ltd Expression of hybrid antibody gene

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2188941A (en) * 1986-04-14 1987-10-14 Bayer Ag Monoclonal antibodies recognizing human interleukin-2-receptor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO8909622A1 *

Also Published As

Publication number Publication date
AU631545B2 (en) 1992-12-03
WO1989009622A1 (en) 1989-10-19
FI895955A0 (en) 1989-12-13
JPH02503867A (en) 1990-11-15
EP0362371A1 (en) 1990-04-11
KR900700134A (en) 1990-08-11
AU3544589A (en) 1989-11-03

Similar Documents

Publication Publication Date Title
EP0362371A4 (en) Il-2 receptor-specific chimeric antibodies
GB8800077D0 (en) Novel chimeric antibodies
HK156695A (en) Novel chimeric antibodies
IL89491A0 (en) Bifunctional chimeric antibodies
IL90017A0 (en) Monoclonal antibodies
ZA898777B (en) Monoclonal antibodies
ZA898499B (en) Anti-fucosylcermiade monoclonal antibody
GB8813527D0 (en) Bispecific antibodies
GB8726230D0 (en) Antibodies
GB2244764A (en) Bonding apparatus
ZA89258B (en) Monoclonal antibodies
ZA891760B (en) Thermo-couples
GB8820036D0 (en) Monoclonal antibodies
GB8812137D0 (en) Antibodies
EP0423333A4 (en) Anti-endoserine antibody
GB2215557B (en) Interface unit
IL106427A0 (en) Bifunctional chimeric antibodies
IL106429A0 (en) Bifunctional chimeric antibodies
ZA891069B (en) Antibodies
GB8812353D0 (en) Antibodies
EP0336441A3 (en) Anti-cpbii monoclonal antibody
IL106426A0 (en) Method for increasing the expression of chimeric antibodies
GB8924417D0 (en) Heterodimer chimeric antibodies
GB8812963D0 (en) Monoclonal antibodies
GB8812962D0 (en) Monoclonal antibodies

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17P Request for examination filed

Effective date: 19900417

A4 Supplementary search report drawn up and despatched

Effective date: 19900905

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: QUEEN, CARY, L.

17Q First examination report despatched

Effective date: 19920904

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19940425